ArticleBMC nephrology2025
Characteristics of indeterminate QuantiFERON-TB Gold PLUS results in pediatric lupus nephritis at Beijing Children's Hospital, 2023-2024.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTuberculosis screening in pediatric lupus nephritis (LN) patients presents unique diagnostic challenges. This study aimed to analyze the frequency of indeterminate QuantiFERON-TB Gold Plus (QFT-Plus) results among children with LN and the potential influence factors.
methodsA retrospective cohort study was conducted among patients under 18 years old with a confirmed diagnosis of LN screened for tuberculosis infection from January 2023 and August 2024. Demographic and clinical data were extracted from their electronic medical record, with categorical variables presented as frequencies and continuous variables as medians. Using SPSS 18.0 (Chicago, IL), we first performed univariate logistic regression to identify factors associated with indeterminate IFN-γ results (P < 0.05), then entered significant variables into multivariate models to determine independent predictors, reporting results as ORs, with statistical significance set at P < 0.05.
resultsOf 111 patients with LN, 49 (44.14%) had indeterminate QFT-Plus results, with 43 (87.76%) due to positive control failure. In the 30-day period prior to the QFT-Plus test, 46 (41.44%) patients were treated with immunotherapy. Univariable logistic regression analysis indicated that the indeterminate group had significantly lower levels of hemoglobin, albumin, and alkaline phosphatase, fewer hospitalizations, and more frequent use of immunotherapy, and higher triglyceride and D-dimers levels. Multivariable logistic regression analysis revealed that triglycerides level (OR 1.847; 95% CI 1.195-2.856; P = 0.006) and immunotherapy use (OR 12.306; 95% CI 3.937-38.463; P<0.0001) were independently associated with increased risk of indeterminate QFT-Plus results. The area under the ROC curve for a triglycerides level of 2.155 mmol/L, and it was 0.751 for discriminating between indeterminate and determinate QFT-Plus results.
conclusionsHospitalized patients with LN had a high rate of an indeterminate QFT-Plus result, predominantly in positive control failure. Besides, our data showed that the use of immunotherapy agents and high triglycerides level represent factors associated with indeterminate QFT-Plus results in our cohort of pediatric lupus nephritis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.